Prevention of parenteral nutrition-associated liver disease: Role of ω-3 fish oil

Current Opinion in Organ Transplantation

Volumn 15, Issue 3, 2010, Pages 334-340

  Fallon, Erica M ^a   Le, Hau D ^a   Puder, Mark ^a  

^a Childrenas Hospital Boston   (United States)

Author keywords

Fish oil; Liver disease; Parenteral nutrition; Short bowel syndrome

Indexed keywords

CLINOLEIC; FISH OIL; INFUSION FLUID; INTRALIPID; LIPID EMULSION; LIPOFUNDIN; LIPOSYN II; OMEGA 3 FATTY ACID; OMEGAVEN; SMOFLIPID; SOYBEAN OIL EMULSION; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING DISORDER; CHILD; CHOLESTASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID SYNTHESIS; FATTY LIVER; GROWTH RETARDATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; LIVER TRANSPLANTATION; LONG TERM CARE; NONHUMAN; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; RECOMMENDED DRUG DOSE; REVIEW; STEATOSIS;

ANIMALS; CHOLESTASIS; EVIDENCE-BASED MEDICINE; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFANT; INTESTINAL ABSORPTION; INTESTINES; LIVER; LIVER DISEASES; MALE; NUTRITIONAL STATUS; PARENTERAL NUTRITION; SHORT BOWEL SYNDROME; SOYBEAN OIL;

EID: 77953258900     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283394879     Document Type: Review

References (54)

1. Howard L, Ament M, Fleming CR, et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology 1995; 109:355-365.
2. Freund HR. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. Nutrition (Burbank, Los Angeles County, Calif) 1991; 7:1-5; discussion -6.
3. Kelly DA. Liver complications of pediatric parenteral nutrition: epidemiology. Nutrition (Burbank, Los Angeles County, Calif) 1998; 14:153-157.
4. Diamanti A, Basso MS, Castro M, et al. Prevalence of life-threatening complications in pediatric patients affected by intestinal failure. Transplant Proc 2007; 39:1632-1633.
5. Chan S, McCowen KC, Bistrian BR, et al. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery 1999; 126:28-34.
6. Christensen RD, Henry E, Wiedmeier SE, et al. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol 2007; 27:284-290.
7. Diamond IR, de Silva N, Pencharz PB, et al. Neonatal short bowel syndrome outcomes after the establishment of the first Canadian multidisciplinary intestinal rehabilitation program: preliminary experience. J Pediatr Surg 2007; 42:806-811.
8. Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr 2001; 139:27-33.
9. Chwals WJ. The metabolic response to surgery in neonates. Curr Opin Pediatr 1994; 6:334-340.
10. Wales PW, de Silva N, Kim JH, et al. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg 2005; 40:755-762.
11. Reyes J, Bueno J, Kocoshis S, et al. Current status of intestinal transplantation in children. J Pediatr Surg 1998; 33:243-254.
12. Wretlind A. Development of fat emulsions. JPEN 1981; 5:230-235.
13. Edgren B, Wretlind A. The theoretical background of the intravenous nutrition with fat emulsions. Nutr Dieta Eur Rev Nutr Diet 1963; 13:364-386.
14. Schuberth O, Wretlind A. Intravenous infusion of fat emulsions, phosphatides and emulsifying agents. Acta Chir Scand 1961; 13 (suppl):S278-S284.
15. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1:420-439.
16. Chen WJ, Yeh SL, Huang PC. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clin Nutr (Edinburgh, Scotland) 1996; 15:24-28.
17. Aksnes J, Eide TJ, Nordstrand K. Lipid entrapment and cellular changes in the rat myocard, lung and liver after long-term parenteral nutrition with lipid emulsion. A light microscopic and ultrastructural study. APMIS 1996; 104:515-522.
18. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition (Burbank, Los Angeles County, Calif) 1998; 14:158-164.
19. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Investig 2001; 108:15-23.
20. Le HD, Meisel JA, de Meijer VE, et al. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 2009; 81:165-170.
21. Calder PC, Sherrington EJ, Askanazi J, Newsholme EA. Inhibition of lymphocyte proliferation in vitro by two lipid emulsions with different fatty acid compositions. Clin Nutr (Edinburgh, Scotland) 1994; 13:69-74.
22. Monson JR, Sedman PC, Ramsden CW, et al. Total parenteral nutrition adversely influences tumour-directed cellular cytotoxic responses in patients with gastrointestinal cancer. Eur J Surg Oncol 1988; 14:935-943.
23. Thomas-Gibson S, Jawhari A, Atlan P, et al. Safe and efficacious prolonged use of an olive oil-based lipid emulsion (ClinOleic) in chronic intestinal failure. Clin Nutr (Edinburgh, Scotland) 2004; 23:697-703.
24. Palova S, Charvat J, Kvapil M. Comparison of soybean oil- and olive oil-based lipid emulsions on hepatobiliary function and serum triacylglycerols level during realimentation. J Int Med Res 2008; 36:587-593.
25. Yeh SL, Chang KY, Huang PC, Chen WJ. Effects of n-3 and n-6 fatty acids on plasma eicosanoids and liver antioxidant enzymes in rats receiving total parenteral nutrition. Nutrition (Burbank, Los Angeles County, Calif) 1997; 13:32-36.
26. Chen WJ, Yeh SL. Effects of fish oil in parenteral nutrition. Nutrition (Burbank, Los Angeles County, Calif) 2003; 19:275-279.
27. Heller AR, Rossel T, Gottschlich B, et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer 2004; 111:611-616.
28. Weiss G, Meyer F, Matthies B, et al. Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr 2002; 87 (Suppl 1):S89-S94.
29. Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN 2004; 28:S39-S70.
30. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132:525-532.
31. Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN 2000; 24:345-350.
32. Alfin-Slater RB, Aftergood L. Essential fatty acids reinvestigated. Physiol Rev 1968; 48:758-784.
33. Crawford MA, Costeloe K, Ghebremeskel K, Phylactos A. The inadequacy of the essential fatty acid content of present preterm feeds. Eur J Pediatr 1998; 157 (Suppl 1):S23-S27. (Pubitemid 128689765)
34. Innis SM. Omega-3 fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations? J Pediatr Gastroenterol Nutr 2009; 48 (Suppl 1):S16-S24.
35. Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003; 171:4837-4843.
36. Novak TE, Babcock TA, Jho DH, et al. NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003; 284:L84-L89.
37. Babcock TA, Novak T, Ong E, et al. Modulation of lipopolysaccharidestimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. J Surg Res 2002; 107:135-139.
38. Alwayn IP, Gura K, Nose V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005; 57:445-452.
39. Alwayn IP, Javid PJ, Gura KM, et al. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. Hepatology (Baltimore, Md) 2004; 39:1176- 1177; author reply 7-8.
40. Alwayn IP, Andersson C, Zauscher B, et al. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005; 79:606-608.
41. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with nonalcoholic fatty liver disease. Clin Sci (Lond) 2004; 106:635-643.
42. Van Aerde JE, Duerksen DR, Gramlich L, et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res 1999; 45:202-208.
43. Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250:395-402.
44. Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678-e686.
45. Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutritionassociated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:e197-e201.
46. Gura KM, Parsons SK, Bechard LJ, et al. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr (Edinburgh, Scotland) 2005; 24:839-847.
47. Lee SI, Valim C, Johnston P, et al. The impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. Pediatr Res 2009; 66:698-703.
48. de Meijer VE, Gura KM, Meisel JA, et al. Parenteral fish oil as monotherapy for patients with parenteral nutrition-associated liver disease. Pediatr Surg Int 2009; 25:123-124.
49. de Meijer VE, Gura KM, Le HD, et al. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN 2009; 33:541-547.
50. Calhoun AW, Sullivan JE. Omegaven for the treatment of parenteral nutrition associated liver disease: a case study. J Ky Med Assoc 2009; 107:55-57.
51. de Meijer VE, Le HD, Meisel JA, et al. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr 2010; 50:212-218.
52. Diamond IR, Sterescu A, Pencharz PB, et al. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48:209-215.
53. Cheung HM, Lam HS, Tam YH, et al. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin Nutr (Edinburgh, Scotland) 2009; 28:209-212.
54. Carlson SE, Cooke RJ, Werkman SH, Tolley EA. First year growth of preterm infants fed standard compared to marine oil n-3 supplemented formula. Lipids 1992; 27:901-907.